Prestige Consumer Healthcare Inc.

NYSE:PBH Stock Report

Market Cap: US$3.9b

Prestige Consumer Healthcare Valuation

Is PBH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PBH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PBH ($77.38) is trading below our estimate of fair value ($154.28)

Significantly Below Fair Value: PBH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PBH?

Key metric: As PBH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PBH. This is calculated by dividing PBH's market cap by their current earnings.
What is PBH's PE Ratio?
PE Ratio18.6x
EarningsUS$205.95m
Market CapUS$3.88b

Price to Earnings Ratio vs Peers

How does PBH's PE Ratio compare to its peers?

The above table shows the PE ratio for PBH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.9x
OGN Organon
2.9x-8.3%US$3.9b
ELAN Elanco Animal Health
28.5x1.6%US$6.0b
SUPN Supernus Pharmaceuticals
34.1x36.2%US$2.1b
CORT Corcept Therapeutics
37.9x41.4%US$5.5b
PBH Prestige Consumer Healthcare
18.6x5.3%US$3.9b

Price-To-Earnings vs Peers: PBH is good value based on its Price-To-Earnings Ratio (18.6x) compared to the peer average (25.9x).

Price to Earnings Ratio vs Industry

How does PBH's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
2.9x-8.3%US$3.88b
NDOI Endo
0.6xn/aUS$1.72b
KPRX Kiora Pharmaceuticals
1.8x-40.4%US$9.87m
SEEL.Q Seelos Therapeutics
0.02xn/aUS$95.91k
PBH 18.6xIndustry Avg. 16.4xNo. of Companies7PE01224364860+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PBH is expensive based on its Price-To-Earnings Ratio (18.6x) compared to the US Pharmaceuticals industry average (16.9x).

Price to Earnings Ratio vs Fair Ratio

What is PBH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PBH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.6x
Fair PE Ratio20.2x

Price-To-Earnings vs Fair Ratio: PBH is good value based on its Price-To-Earnings Ratio (18.6x) compared to the estimated Fair Price-To-Earnings Ratio (20.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PBH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$77.38
US$85.29
+10.2%
9.4%US$95.00US$70.00n/a7
Dec ’25US$84.77
US$85.29
+0.6%
9.4%US$95.00US$70.00n/a7
Nov ’25US$74.05
US$79.43
+7.3%
10.3%US$95.00US$68.00n/a7
Oct ’25US$70.83
US$79.43
+12.1%
10.3%US$95.00US$68.00n/a7
Sep ’25US$74.64
US$79.17
+6.1%
10.5%US$95.00US$68.00n/a6
Aug ’25US$70.55
US$78.17
+10.8%
10.2%US$93.00US$68.00n/a6
Jul ’25US$67.75
US$78.17
+15.4%
10.2%US$93.00US$68.00n/a6
Jun ’25US$64.31
US$73.50
+14.3%
8.0%US$81.00US$65.00n/a6
May ’25US$71.12
US$74.33
+4.5%
8.7%US$84.00US$65.00n/a6
Apr ’25US$71.68
US$74.33
+3.7%
8.7%US$84.00US$65.00n/a6
Mar ’25US$70.13
US$74.33
+6.0%
8.7%US$84.00US$65.00n/a6
Feb ’25US$62.53
US$71.50
+14.3%
10.2%US$82.00US$60.00n/a6
Jan ’25US$61.22
US$71.50
+16.8%
10.2%US$82.00US$60.00n/a6
Dec ’24US$58.61
US$71.50
+22.0%
10.2%US$82.00US$60.00US$84.776
Nov ’24US$59.51
US$72.80
+22.3%
10.5%US$82.00US$60.00US$74.055
Oct ’24US$57.19
US$72.80
+27.3%
10.5%US$82.00US$60.00US$70.835
Sep ’24US$58.37
US$72.80
+24.7%
10.5%US$82.00US$60.00US$74.645
Aug ’24US$65.37
US$72.20
+10.4%
10.8%US$82.00US$60.00US$70.555
Jul ’24US$59.43
US$72.20
+21.5%
10.8%US$82.00US$60.00US$67.755
Jun ’24US$56.70
US$72.20
+27.3%
10.8%US$82.00US$60.00US$64.315
May ’24US$62.46
US$71.00
+13.7%
10.8%US$82.00US$60.00US$71.125
Apr ’24US$62.63
US$70.83
+13.1%
9.9%US$82.00US$60.00US$71.686
Mar ’24US$60.54
US$70.83
+17.0%
9.9%US$82.00US$60.00US$70.136
Feb ’24US$66.19
US$70.50
+6.5%
10.5%US$82.00US$60.00US$62.536
Jan ’24US$62.60
US$66.50
+6.2%
7.0%US$72.00US$60.00US$61.226
Dec ’23US$62.81
US$66.50
+5.9%
7.0%US$72.00US$60.00US$58.616

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 05:34
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prestige Consumer Healthcare Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olivia Tong CheangBofA Global Research
Linda Bolton-WeiserB. Riley Securities, Inc.
Susan AndersonCanaccord Genuity